The Protocol Review Committee (PRC) is a multi-disciplinary committee whose mission is to provide scientific review for all clinical protocols involving cancer patients at the University of Iowa Hospitals and Clinics, or UICC resources. This review includes any protocol that: 1) involves patients seen in the John and Marry Pappajohn Clinical Cancer Center or cancer patients from other units in the hospital such as the Bone Marrow Transplantation Unit, Radiation Therapy, the General Clinical Research Center, and the Oncology ward of the Children's Hospital of Iowa or 2) uses UICC resources such as the Core facilities. The role of the PRC is complementary to that of the IRB The PRC is complementary to that of the IRB. The PRC ensures that 1) institutional protocols have adequate scientific rationale to justify the hypothesis, 2) experimental design is rational and includes a clearly stated valid statistical section, a realistic assessment of accrual and appropriate response parameters, 3) the scientific question to be answered is of sufficient interest to justify use of UICC resources, 4) investigators have considered all potential basic science correlates that might be pursued as part of their studies, and 5) studies are prioritized that deal with similar patient populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-03
Application #
6658349
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-07-01
Project End
2003-06-30
Budget Start
Budget End
Support Year
3
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Mayo, Zachary; Seyedin, Steven; Marquardt, Michael et al. (2018) Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report. Head Neck :
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182
Beck, Anna C; Goffredo, Paolo; Hassan, Imran et al. (2018) Risk factors for 30-day readmission after adrenalectomy. Surgery 164:766-773
Gorman, Jacob V; Colgan, John D (2018) Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function. Immunology 154:418-433
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Fama, Angelo; Xiang, Jinhua; Link, Brian K et al. (2018) Human Pegivirus infection and lymphoma risk and prognosis: a North American study. Br J Haematol 182:644-653
Xiu, Yan; Dong, Qianze; Li, Qingchang et al. (2018) Stabilization of NF-?B-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia. Cell Rep 22:350-358
Armer, Jessica S; Clevenger, Lauren; Davis, Lauren Z et al. (2018) Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer 124:3401-3408
Spencer Noakes, T Leigh; Przybycien, Thomas S; Forwell, Amanda et al. (2018) Brain Development and Heart Function after Systemic Single-Agent Chemotherapy in a Mouse Model of Childhood Leukemia Treatment. Clin Cancer Res 24:6040-6052

Showing the most recent 10 out of 1080 publications